Volastra Therapeutics, Inc. — Form D

Volastra Therapeutics, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2024-05-30. The offering totals $15.0M, of which $15.0M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (26)

Showing 25 of 26 people.

NameRoleLocation
Samuel Zolot BakhoumDirectorNew York, NY
Arjun Zolot BalarDirectorNew York, NY
Rez Zolot HalzeDirectorNew York, NY
Charles Hugh-JonesDirectorNew York, NY
Eileen Zolot McGuireDirectorNew York, NY
David Zolot NicholsonDirectorNew York, NY
Sandra Zolot PetersonDirectorNew York, NY
Stefan Zolot VitorovicDirectorNew York, NY
Scott DrutmanExecutive OfficerNew York, NY
Charles Hugh-JonesExecutive OfficerNew York, NY
Rachel Zolot SchwartzExecutive OfficerNew York, NY
Amy SchulmanDirectorCambridge, MA
Sandra PetersonDirectorNEW YORK, NY
Sandra PetersonExecutive OfficerNEW YORK, NY
Robert MittendorffDirectorSAN FRANCISCO, CA
Jill GoldsteinDirectorNEW YORK, NY
David SouthwellDirectorNEW YORK, NY
David SouthwellExecutive OfficerNEW YORK, NY
Arjun BalarDirectorNEW YORK, NY
Samuel BakhoumDirectorNEW YORK, NY
Ellie McGuireDirectorNEW YORK, NY
Luc DochezDirectorNEW YORK, NY
David NicholsonDirectorCarlsbad, CA
Diane TagerExecutive OfficerNew York, NY
Michael SuExecutive OfficerNew York, NY

Other filings by this issuer (2)

FiledFormOfferingSold
2025-09-23D$30.1M$30.1M
2023-03-13D$60.2M$60.2M

More